Will MRI screening deliver the expected survival advantage in BRCA 1 carriers?

Will MRI screening deliver the expected survival advantage in BRCA 1 carriers?
L.J. Hamilton, A.J. Evans, E.J. Cornford, E.A. Rakha, I.O. Ellis, W.D. Foulkes
Clinical Radiology (2009) 64, 1045-1047

Link to Journal

Magnetic resonance imaging (MRI) screening for breast cancer has greater sensitivity than conventional mammographic screening.1,2 Digital mammography gives maximum sensitivity in younger women with denser breasts.3 Combining MRI with digital mammography is likely to give maximum sensitivity. This additional sensitivity offered by MRI has the potential to identify breast cancer at an earlier stage, when the tumours are smaller in size and are not associated with metastases to regional lymph nodes

It is of vital importance that actual mortality data on a cohort of MRI-screened BRCA1 carriers without prior breast cancer are published to en- able an informed decision on the benefits of MRI screening in this group. Until such mortality data are available, the predicted benefits must remain just that - predictions. We urge caution until such time as prospective survival data are available